keyword
MENU ▼
Read by QxMD icon Read
search

IDC Prostate cancer

keyword
https://www.readbyqxmd.com/read/29878934/comedonecrosis-revisited-strong-association-with-intraductal-carcinoma-of-the-prostate
#1
Samson W Fine, Hikmat A Al-Ahmadie, Ying-Bei Chen, Anuradha Gopalan, Satish K Tickoo, Victor E Reuter
From the advent of the Gleason grading system for prostate cancer, cancer displaying intraluminal necrotic cells and/or karyorrhexis within cribriform/solid architecture, a phenomenon termed "comedonecrosis," has been assigned pattern 5. Intraductal carcinoma (IDC-P) shows morphologic overlap with high-grade cribriform/solid adenocarcinoma architecturally and cytologically and may also show central necrosis, yet due to the presence of basal cells at the duct periphery is not currently assigned a grade in clinical practice...
August 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29772102/novel-nomograms-for-castration-resistant-prostate-cancer-and-survival-outcome-in-patients-with-de-novo-bone-metastatic-prostate-cancer
#2
Jinge Zhao, Guangxi Sun, Banghua Liao, Xingming Zhang, Cameron M Armstrong, Xiaoxue Yin, Jiandong Liu, Junru Chen, Yaojing Yang, Peng Zhao, Qidun Tang, Zhenghao Wang, Zhibin Chen, Xiong Li, Qiang Wei, Xiang Li, Ni Chen, Allen C Gao, Pengfei Shen, Hao Zeng
OBJECTIVES: To develop nomograms predicting the incidence of castration-resistant prostate cancer (CRPC) and overall survival (OS) for de novo metastatic prostate cancer (PCa). PATIENTS AND METHODS: Data from 449 patients with de novo metastatic PCa were retrospectively analysed. Patients were randomly divided into a training (n = 314, 70%) and a validation cohort (n = 135, 30%). Predictive factors were selected using a Cox proportional hazards model and were further used for building predictive models...
May 17, 2018: BJU International
https://www.readbyqxmd.com/read/29603326/the-impact-of-intraductal-carcinoma-of-the-prostate-on-the-site-and-timing-of-recurrence-and-cancer-specific-survival
#3
Vincent Q Trinh, Jennifer Sirois, Nazim Benzerdjeb, Babak K Mansoori, Andrée-Anne Grosset, Roula Albadine, Mathieu Latour, Anne-Marie Mes-Masson, Hélène Hovington, Alain Bergeron, Martin Ladouceur, Yves Fradet, Fred Saad, Dominique Trudel
BACKGROUND: To investigate the effect of intraductal carcinoma of the prostate (IDC-P) in radical prostatectomy (RP) specimens in the context of the site of recurrence, time to recurrence, and cancer-specific survival in two academic cohorts of locally, regionally, or distantly recurrent prostate cancer. METHODS: Our cohort included men enrolled into two academic tissue repositories from 1993 to 2011, who were treated with first-line RP who later experienced local recurrence, regional recurrence, or distant metastasis (together termed clinical recurrence, CR)...
July 2018: Prostate
https://www.readbyqxmd.com/read/29408568/role-of-magnetic-resonance-imaging-targeted-biopsy-in-detection-of-prostate-cancer-harboring-adverse-pathological-features-of-intraductal-carcinoma-and-invasive-cribriform-carcinoma
#4
Susan Prendeville, Mark Gertner, Manjula Maganti, Melania Pintilie, Nathan Perlis, Ants Toi, Andrew J Evans, Antonio Finelli, Theodorus H van der Kwast, Sangeet Ghai
PURPOSE: The aim of this study was to compare biopsy detection of intraductal and cribriform pattern invasive prostate carcinoma in multiparametric magnetic resonance imaging positive and negative regions of the prostate. MATERIALS AND METHODS: We queried a prospectively maintained, single institution database to identify patients who underwent multiparametric magnetic resonance imaging/ultrasound fusion targeted biopsy and concurrent systematic sextant biopsy of magnetic resonance imaging negative regions between January 2013 and May 2016...
July 2018: Journal of Urology
https://www.readbyqxmd.com/read/29397469/efficacy-of-docetaxel-in-castration-resistant-prostate-cancer-patients-with-intraductal-carcinoma-of-the-prostate
#5
Akiyuki Yamamoto, Masashi Kato, Hirotaka Matsui, Ryo Ishida, Tohru Kimura, Yasuhito Funahashi, Naoto Sassa, Yoshihisa Matsukawa, Osamu Kamihira, Ryohei Hattori, Momokazu Gotoh, Toyonori Tsuzuki
BACKGROUND: This study aimed to investigate the efficacy of docetaxel in castration-resistant prostate cancer (CRPC) patients with intraductal carcinoma of the prostate (IDC-P). PATIENTS AND METHODS: We retrospectively identified 79 CRPC patients with distant metastasis at initial diagnosis from June 2002 to January 2014. All patients received initial androgen deprivation therapy and 46 received docetaxel chemotherapy after progressing to CRPC. The primary outcome of interest was cancer-specific survival (CSS) from the time of CRPC diagnosis...
June 2018: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29295717/cribriform-and-intraductal-prostate-cancer-are-associated-with-increased-genomic-instability-and-distinct-genomic-alterations
#6
René Böttcher, Charlotte F Kweldam, Julie Livingstone, Emilie Lalonde, Takafumi N Yamaguchi, Vincent Huang, Fouad Yousif, Michael Fraser, Robert G Bristow, Theodorus van der Kwast, Paul C Boutros, Guido Jenster, Geert J L H van Leenders
BACKGROUND: Invasive cribriform and intraductal carcinoma (CR/IDC) is associated with adverse outcome of prostate cancer patients. The aim of this study was to determine the molecular aberrations associated with CR/IDC in primary prostate cancer, focusing on genomic instability and somatic copy number alterations (CNA). METHODS: Whole-slide images of The Cancer Genome Atlas Project (TCGA, N = 260) and the Canadian Prostate Cancer Genome Network (CPC-GENE, N = 199) radical prostatectomy datasets were reviewed for Gleason score (GS) and presence of CR/IDC...
January 2, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29094384/prognostic-parameter-for-high-risk-prostate-cancer-patients-at-initial-presentation
#7
Masashi Kato, Kyosuke Kimura, Akihiro Hirakawa, Yumiko Kobayashi, Ryo Ishida, Osamu Kamihira, Tsuyoshi Majima, Yasuhito Funahashi, Naoto Sassa, Yoshihisa Matsukawa, Ryohei Hattori, Momokazu Gotoh, Toyonori Tsuzuki
BACKGROUND: High-risk prostate cancer can be defined by a patient's Gleason score (GS), prostate-specific antigen (PSA) level, and clinical T (cT) stage, but a novel marker is needed due to heterogeneity of the disease. In this study, we evaluated whether intraductal carcinoma of the prostate (IDC-P) confirmed by needle biopsy is an adverse prognostic parameter for progression-free survival (PFS) and cancer-specific survival (CSS) in patients with high-risk prostate cancer. METHODS: We retrospectively evaluated 204 patients with high-risk prostate cancer treated by radical prostatectomy from 1991 to 2005 at Nagoya University and its affiliated hospitals...
January 2018: Prostate
https://www.readbyqxmd.com/read/28977728/intraductal-carcinoma-of-the-prostate-can-evade-androgen-deprivation-with-emergence-of-castrate-tolerant-cells
#8
Laura H Porter, Kohei Hashimoto, Mitchell G Lawrence, Carmel Pezaro, David Clouston, Hong Wang, Melissa Papargiris, Heather Thorne, Jason Li, Andrew Ryan, Sam Norden, Daniel Moon, Damien M Bolton, Shomik Sengupta, Mark Frydenberg, Declan G Murphy, Gail P Risbridger, Renea A Taylor
OBJECTIVE: To determine the relevance of intraductal carcinoma of the prostate (IDC-P) in advanced prostate cancer by first examining whether IDC-P was originally present in patients who later developed advanced prostate cancer and then using patient-derived xenografts (PDXs) to investigate the response of IDC-P to androgen deprivation therapy (ADT). MATERIALS AND METHODS: We conducted a retrospective pathology review of IDC-P in primary prostate biopsy or surgery specimens from 38 men who subsequently developed advanced prostate cancer...
June 2018: BJU International
https://www.readbyqxmd.com/read/28975495/evaluation-of-tumor-morphologies-and-association-with-biochemical-recurrence-after-radical-prostatectomy-in-grade-group-5-prostate-cancer
#9
Trevor A Flood, Nicola Schieda, Jordan Sim, Rodney H Breau, Chris Morash, Eric C Belanger, Susan J Robertson
We assessed Gleason pattern 5 (GP5) and other prostatic adenocarcinoma (PCa) morphologies to determine their association with biochemical recurrence (BCR). A search for grade group 5 PCa with radical prostatectomy (RP) yielded 49 patients. RPs were reviewed for %GP5 and morphologies (sheets, single cells, cords, small solid cylinders, solid medium to large nests with rosette-like spaces [SMLNRS], comedonecrosis, cribriform glands, glomerulations, intraductal carcinoma of the prostate [IDC-P], and prostatic ductal adenocarcinoma [PDCa])...
February 2018: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28903426/the-prognostic-implication-of-intraductal-carcinoma-of-the-prostate-in-metastatic-castration-resistant-prostate-cancer-and-its-potential-predictive-value-in-those-treated-with-docetaxel-or-abiraterone-as-first-line-therapy
#10
Jinge Zhao, Pengfei Shen, Guangxi Sun, Ni Chen, Jiandong Liu, Xin Tang, Rui Huang, Diming Cai, Jing Gong, Xingming Zhang, Zhibin Chen, Xiang Li, Qiang Wei, Peng Zhang, Zhenhua Liu, Jiyan Liu, Hao Zeng
Intraductal carcinoma of the prostate (IDC-P) is recognized as a newly pathological entity in 2016 WHO classification. It's role in metastatic castration-resistant prostate cancer (CRPC) remains obscure. We aimed to explore the association of IDC-P with clinical outcome and to further identify its potential predictive role in making first-line treatment decisions for mCRPC. We retrospectively analyzed data of 131 mCRPC patients. IDC-P was diagnosed by re-biopsy at the time of mCRPC. Among total patients, 45 and 41 received abiraterone or docetaxel as first-line therapies, respectively...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28598696/pathology-and-molecular-updates-in-tumors-of-the-prostate-towards-a-personalized-approach
#11
REVIEW
Silvia Gasparrini, Alessia Cimadamore, Roberta Mazzucchelli, Marina Scarpelli, Francesco Massari, Maria Rosaria Raspollini, Andrea B Galosi, Antonio Lopez-Beltran, Liang Cheng, Rodolfo Montironi
Treatment planning in patients with prostate neoplasms and prostate cancer (PCa) is generally based on the clinical and pathological molecular markers obtained from prostate needle biopsy and/or radical prostatectomy specimens. Area covered: Pathology of prostate neoplasms is evolving rapidly. Emerging trends include new additions to the 2016 World Health Organization (WHO) tumor classification as well as expanded diagnostic utility of biomarkers and molecular testing in tissue specimens, liquid biopsies and urinary samples, with the following purposes: diagnosis, prognosis and prediction...
August 2017: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/28511883/a-prostate-cancer-nimbosus-genomic-instability-and-schlap1-dysregulation-underpin-aggression-of-intraductal-and-cribriform-subpathologies
#12
MULTICENTER STUDY
Melvin L K Chua, Winnie Lo, Melania Pintilie, Jure Murgic, Emilie Lalonde, Vinayak Bhandari, Osman Mahamud, Anuradha Gopalan, Charlotte F Kweldam, Geert J L H van Leenders, Esther I Verhoef, Agnes Marije Hoogland, Julie Livingstone, Alejandro Berlin, Alan Dal Pra, Alice Meng, Junyan Zhang, Michèle Orain, Valérie Picard, Hélène Hovington, Alain Bergeron, Louis Lacombe, Yves Fradet, Bernard Têtu, Victor E Reuter, Neil Fleshner, Michael Fraser, Paul C Boutros, Theodorus H van der Kwast, Robert G Bristow
BACKGROUND: Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable subpathologies in localized prostate cancer. We recently showed that IDC shares a clonal ancestry with the adjacent glandular adenocarcinoma. OBJECTIVE: We investigated for the co-occurrence of "aggression" factors, genomic instability and hypoxia, and performed gene expression profiling of these tumors. DESIGN, SETTING, AND PARTICIPANTS: A total of 1325 men were treated for localized prostate cancer from four academic institutions (University Health Network, CHU de Québec-Université Laval, Memorial Sloan Kettering Cancer Center [MSKCC], and Erasmus Medical Center)...
November 2017: European Urology
https://www.readbyqxmd.com/read/28423709/prognostic-values-of-clinicopathological-characteristics-and-survival-outcomes-in-prostate-infiltrating-ductal-carcinoma-a-population-based-study
#13
Yu-Peng Wu, Shao-Hao Chen, Shi-Tao Wang, Xiao-Dong Li, Hai Cai, Yun-Zhi Lin, Xue-Yi Xue, Yong Wei, Qing-Shui Zheng, Ning Xu
Infiltrating ductal carcinoma (IDC) is a rare histologic subtype of prostate cancer. We investigated the clinicopathological features and prognosis of IDC compared with acinar cell carcinoma (ACC). We identified 3814 men diagnosed with prostate cancer between 2004 to and 2013 in the Surveillance, Epidemiology, and End Results database, including 511 IDC and 3303 ACC cases. Prostate cancer-specific survival (PCSS) was compared using univariate and multivariate Cox proportional hazards models. Generally, IDC occurred in older men (≥ 65 years old) and presented with larger sizes, and higher grades, American Joint Committee on Cancer (AJCC) stages, AJCC T stages, lymph node positive rates and metastasis rates...
April 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28422303/smoking-increased-the-risk-of-prostate-cancer-with-grade-group%C3%A2-%C3%A2-%C3%A2-4-and-intraductal-carcinoma-in-a-prospective-biopsy-cohort
#14
Bo Tang, Cheng-Tao Han, Hua-Lei Gan, Gui-Ming Zhang, Cui-Zhu Zhang, Wei-Yi Yang, Ying Shen, Yao Zhu, Ding-Wei Ye
OBJECTIVE: To investigate the association between smoking and different prostate cancer (PCa) pathological subtypes incidence in Chinese men. PATIENTS AND METHODS: We prospectively included 1795 patients who underwent prostate biopsies in one tertiary center between March 2013 and April 2016. Clinical data and biopsy outcomes were collected. Logistic regression was used to evaluate the association between cigarette smoking and PCa incidence. RESULTS: A total of 737 men, 480 men and 58 men were diagnosed with PCa, high-grade PCa (HGPCa, grade group ≥ 4 as accepted by the 2014 ISUP) and intraductal carcinoma of the prostate (IDC-P), respectively...
June 2017: Prostate
https://www.readbyqxmd.com/read/28342640/systematic-review-links-the-prevalence-of-intraductal-carcinoma-of-the-prostate-to-prostate-cancer-risk-categories
#15
REVIEW
Laura H Porter, Mitchell G Lawrence, Dragan Ilic, David Clouston, Damien M Bolton, Mark Frydenberg, Declan G Murphy, Carmel Pezaro, Gail P Risbridger, Renea A Taylor
Intraductal carcinoma of the prostate (IDC-P) is associated with poor prognosis. While it is often regarded as a rare pathology, the prevalence of IDC-P remains unclear, with variable reports from small and disparate patient populations. To determine how common IDC-P is across the spectrum of prostate cancer, we conducted a systematic review correlating IDC-P prevalence with prostate cancer risk. Electronic searches of the OVID Medline, PubMed, and Scopus literature databases identified 38 patient cohorts in 24 articles, which were divided between four prostate cancer risk categories (low, moderate, high, and recurrent or metastatic disease)...
October 2017: European Urology
https://www.readbyqxmd.com/read/28306557/mri-micturating-urethrography-for-improved-urethral-delineation-in-prostate-radiotherapy-planning-a-case-study
#16
Robba Rai, Mark Sidhom, Karen Lim, Lucy Ohanessian, Gary P Liney
Stereotactic ablative body radiotherapy is used in prostate cancer to deliver a high dose of radiation to the tumour over a small number of treatments. This involves the simulation of the patient using both CT and MRI. Current practice is to insert an indwelling catheter (IDC) during CT to assist with visualisation of the urethra and subsequently minimise dose to this highly critical structure. However, this procedure is invasive and has an associated risk of infection. This is a case study, which demonstrates our initial experience of using a real-time non-invasive MRI technique to replace the use of IDC for prostate cancer patients...
April 21, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28240424/intraductal-carcinoma-of-the-prostate-on-diagnostic-needle-biopsy-predicts-prostate-cancer-mortality-a-population-based-study
#17
Thorstein Saeter, Ljiljana Vlatkovic, Gudmund Waaler, Einar Servoll, Jahn M Nesland, Karol Axcrona, Ulrika Axcrona
BACKGROUND: Intraductal carcinoma of the prostate (IDC-P) is a distinct histopathologic feature associated with high-grade, advanced prostate cancer. Although studies have shown that IDC-P is a predictor of progression following surgical or radiation treatment for prostate cancer, there are sparse data regarding IDC-P on diagnostic needle biopsy as a prognosticator of prostate cancer mortality. MATERIALS AND METHODS: This was a population-based study of all prostate cancer patients diagnosed using needle biopsy and without evidence of systemic disease between 1991 and 1999 within a defined geographic region of Norway...
June 2017: Prostate
https://www.readbyqxmd.com/read/28162815/improving-the-rotterdam-european-randomized-study-of-screening-for-prostate-cancer-risk-calculator-for-initial-prostate-biopsy-by-incorporating-the-2014-international-society-of-urological-pathology-gleason-grading-and-cribriform-growth
#18
Monique J Roobol, Jan F M Verbeek, Theo van der Kwast, Intan P Kümmerlin, Charlotte F Kweldam, Geert J L H van Leenders
BACKGROUND: The survival rate for men with International Society of Urological Pathology (ISUP) grade 2 prostate cancer (PCa) without invasive cribriform (CR) and intraductal carcinoma (IDC) is similar to that for ISUP grade 1. If updated into the European Randomized Study of Screening for Prostate Cancer (ERSPC Rotterdam) risk calculator number 3 (RC3), this may further improve upfront selection of men who need a biopsy. OBJECTIVE: To improve the number of possible biopsies avoided, while limiting undiagnosed clinically important PCa by applying the updated RC3 for risk-based patient selection...
July 2017: European Urology
https://www.readbyqxmd.com/read/28067867/germline-brca2-mutations-drive-prostate-cancers-with-distinct-evolutionary-trajectories
#19
Renea A Taylor, Michael Fraser, Julie Livingstone, Shadrielle Melijah G Espiritu, Heather Thorne, Vincent Huang, Winnie Lo, Yu-Jia Shiah, Takafumi N Yamaguchi, Ania Sliwinski, Sheri Horsburgh, Alice Meng, Lawrence E Heisler, Nancy Yu, Fouad Yousif, Melissa Papargiris, Mitchell G Lawrence, Lee Timms, Declan G Murphy, Mark Frydenberg, Julia F Hopkins, Damien Bolton, David Clouston, John D McPherson, Theodorus van der Kwast, Paul C Boutros, Gail P Risbridger, Robert G Bristow
Germline mutations in the BRCA2 tumour suppressor are associated with both an increased lifetime risk of developing prostate cancer (PCa) and increased risk of aggressive disease. To understand this aggression, here we profile the genomes and methylomes of localized PCa from 14 carriers of deleterious germline BRCA2 mutations (BRCA2-mutant PCa). We show that BRCA2-mutant PCa harbour increased genomic instability and a mutational profile that more closely resembles metastastic than localized disease. BRCA2-mutant PCa shows genomic and epigenomic dysregulation of the MED12L/MED12 axis, which is frequently dysregulated in metastatic castration-resistant prostate cancer (mCRPC)...
January 9, 2017: Nature Communications
https://www.readbyqxmd.com/read/27614104/reporting-intraductal-carcinoma-of-the-prostate-a-plea-for-greater-standardization
#20
LETTER
Murali Varma, Lars Egevad, Brett Delahunt, Glen Kristiansen
No abstract text is available yet for this article.
February 2017: Histopathology
keyword
keyword
167976
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"